NuVasive (Nasdaq:NUVA) - Prezzo delle azioni, notizie e analisi

NUVA Panoramica delle azioni

NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. Maggiori dettagli

NUVA analisi fondamentale
Punteggio fiocco di neve
Valutazione	3/6
Crescita futura	3/6
Prestazioni passate	1/6
Salute finanziaria	3/6
Dividendi	0/6

Premi

Negoziato a 47.4% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 46.22% all'anno

È diventato redditizio quest'anno

Gli analisti concordano sul fatto che il prezzo delle azioni salirà di 23.3%

Analisi del rischio

Il debito non è ben coperto dal flusso di cassa operativo

Grandi elementi una tantum che incidono sui risultati finanziari

NuVasive, Inc. Concorrenti

CONMED

NYSE:CNMD

US$2.2b

LeMaitre Vascular

NasdaqGM:LMAT

US$2.3b

LivaNova

NasdaqGS:LIVN

US$2.7b

InMode

NasdaqGS:INMD

US$1.5b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per NuVasive
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$39.75
Massimo di 52 settimane	US$49.53
Minimo di 52 settimane	US$35.17
Beta	1.07
1Variazione di 1 mese	-0.63%
Variazione a 3 mesi	0.84%
Variazione di 1 anno	-8.30%
3Variazione a 3 anni	-22.24%
Variazione a 5 anni	-42.71%
Variazione dall'IPO	248.68%

Notizie e aggiornamenti recenti

Recent updates

Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?

Apr 18

What Does NuVasive, Inc.'s (NASDAQ:NUVA) Share Price Indicate?

Jan 24

NuVasive, Inc.'s (NASDAQ:NUVA) Intrinsic Value Is Potentially 48% Above Its Share Price

Dec 31

Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal

Dec 05

These 4 Measures Indicate That NuVasive (NASDAQ:NUVA) Is Using Debt Reasonably Well

Nov 13

NuVasive Non-GAAP EPS of $0.47 misses by $0.09, revenue of $310.5M beats by $4.12M

Aug 03

NuVasive: Industry Tailwinds More Than Fairly Priced

Jun 13

Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)

Jun 01

Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

May 11

NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet

Apr 20

At US$56.32, Is NuVasive, Inc. (NASDAQ:NUVA) Worth Looking At Closely?

Mar 30

NuVasive's Turnaround Story Needs A Boost From Better Results

Mar 01

Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

Dec 28

Should You Think About Buying NuVasive, Inc. (NASDAQ:NUVA) Now?

Dec 02

NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet

Nov 11

NuVasive, Inc. (NASDAQ:NUVA) Shares Could Be 32% Below Their Intrinsic Value Estimate

Oct 21

Be Wary Of NuVasive (NASDAQ:NUVA) And Its Returns On Capital

Sep 29

At US$59.79, Is It Time To Put NuVasive, Inc. (NASDAQ:NUVA) On Your Watch List?

Aug 18

NuVasive Still Getting No Love With COVID-19 And Competitive Worries

Aug 12

Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?

Jul 27

Are Investors Undervaluing NuVasive, Inc. (NASDAQ:NUVA) By 21%?

Jun 17

Some Investors May Be Worried About NuVasive's (NASDAQ:NUVA) Returns On Capital

May 30

Why We Think NuVasive, Inc.'s (NASDAQ:NUVA) CEO Compensation Is Not Excessive At All

May 12

Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?

Mar 30

Is Now The Time To Look At Buying NuVasive, Inc. (NASDAQ:NUVA)?

Mar 09

Need To Know: NuVasive, Inc. (NASDAQ:NUVA) Insiders Have Been Buying Shares

Feb 16

A Look At The Fair Value Of NuVasive, Inc. (NASDAQ:NUVA)

Jan 26

NuVasive stock gains on study results of its X360 surgery approach

Jan 06

What Type Of Returns Would NuVasive's(NASDAQ:NUVA) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Jan 05

Rendimenti per gli azionisti

	NUVA	US Medical Equipment	US Mercato
7D	1.5%	1.7%	0.3%
1Y	-8.3%	21.4%	31.1%

Ritorno vs Industria: NUVA ha avuto una performance inferiore rispetto al US Medical Equipment che ha registrato un rendimento 21.4 % nell'ultimo anno.

Rendimento vs Mercato: NUVA ha avuto una performance inferiore al mercato US che ha registrato un rendimento 31.1 % nell'ultimo anno.

Volatilità dei prezzi

Is NUVA's price volatile compared to industry and market?
NUVA volatility
NUVA Average Weekly Movement	3.8%
Medical Equipment Industry Average Movement	8.0%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Prezzo delle azioni stabile: NUVA non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 4% ) di NUVA è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1997	3,000	Chris Barry	www.nuvasive.com

NuVasive, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di NuVasive con la sua capitalizzazione di mercato?
NUVA statistiche fondamentali
Capitalizzazione di mercato	US$2.08b
Guadagni(TTM)	US$28.45m
Ricavi(TTM)	US$1.23b

73.3x

Rapporto P/E

1.7x

Rapporto P/S

NUVA è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
NUVA Conto economico (TTM)
Ricavi	US$1.23b
Costo del fatturato	US$347.50m
Profitto lordo	US$878.73m
Altre spese	US$850.28m
Guadagni	US$28.45m

Ultimi guadagni dichiarati

Jun 30, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	0.54
Margine lordo	71.66%
Margine di profitto netto	2.32%
Rapporto debito/patrimonio netto	89.1%

Come si è comportato NUVA nel lungo periodo?

Vedi performance storica e confronto

NUVA Panoramica delle azioni

Premi

Analisi del rischio

NuVasive, Inc. Concorrenti

NYSE:CNMD

US$2.2b

NasdaqGM:LMAT

US$2.3b

NasdaqGS:LIVN

US$2.7b

NasdaqGS:INMD

US$1.5b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

NuVasive Files Form 15

NuVasive, Inc.(NasdaqGS:NUVA) dropped from NASDAQ Composite Index

Globus Medical, Inc. (NYSE:GMED) completed the acquisition of NuVasive, Inc. (NasdaqGS:NUVA) from BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc., Thrivent Financial for Lutherans and others.

Globus Medical, Inc. (NYSE:GMED) completed the acquisition of NuVasive, Inc. (NasdaqGS:NUVA) from BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc., Thrivent Financial for Lutherans and others.

Consensus EPS estimates fall by 19%

New minor risk - Earnings quality

Recent updates

NuVasive Files Form 15

NuVasive, Inc.(NasdaqGS:NUVA) dropped from NASDAQ Composite Index

Globus Medical, Inc. (NYSE:GMED) completed the acquisition of NuVasive, Inc. (NasdaqGS:NUVA) from BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc., Thrivent Financial for Lutherans and others.

Globus Medical, Inc. (NYSE:GMED) completed the acquisition of NuVasive, Inc. (NasdaqGS:NUVA) from BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc., Thrivent Financial for Lutherans and others.

Consensus EPS estimates fall by 19%

New minor risk - Earnings quality

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

NuVasive, Inc. Provides Sales Guidance for the Full Year 2023

NuVasive, Inc. to Report Q2, 2023 Results on Aug 02, 2023

NuVasive, Inc. Announces Resignation of Marc Rosenbaum as Vice President, Corporate Controller and Chief Accounting Officer

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

NuVasive, Inc. Provides Sales Guidance for the Year 2023

NuVasive, Inc., Annual General Meeting, Jun 09, 2023

NuVasive, Inc. to Report Q1, 2023 Results on May 10, 2023

Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?

CEO & Director exercised options and sold US$491k worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations

Globus Medical, Inc. (NYSE:GMED) entered into a definitive agreement to acquire NuVasive, Inc. (NasdaqGS:NUVA) for $3.1 billion.

NuVasive, Inc. to Report Q4, 2022 Results on Feb 22, 2023

What Does NuVasive, Inc.'s (NASDAQ:NUVA) Share Price Indicate?

NuVasive, Inc.'s (NASDAQ:NUVA) Intrinsic Value Is Potentially 48% Above Its Share Price

Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal

Price target decreased to US$49.25

These 4 Measures Indicate That NuVasive (NASDAQ:NUVA) Is Using Debt Reasonably Well

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

NuVasive, Inc. Revises Earnings Guidance for the Year 2022

NuVasive, Inc. Launches Tube System and Excavation Micro for Posterior Spine Surgery

NuVasive, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Price target decreased to US$56.00

Nuvasive Launches Reline Cervical for Posterior Cervical Fusion as Part of the C360 Portfolio

Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)

Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal

NuVasive Likely Undervalued, But It's Hard To Find Catalysts

Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?

NuVasive, Inc. Announces Departure of Massimo Calafiore as Executive Vice President and Chief Commercial Officer, Effective August 31, 2022

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

NuVasive, Inc. Revises Earnings Guidance for the Full Year of 2022

NuVasive Non-GAAP EPS of $0.47 misses by $0.09, revenue of $310.5M beats by $4.12M

NuVasive, Inc. to Report Q2, 2022 Results on Aug 03, 2022

NuVasive: Industry Tailwinds More Than Fairly Priced

Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)

NuVasive, Inc. Announces Management Changes

Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

Now 21% undervalued after recent price drop

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

NuVasive, Inc. Revises Earnings Guidance for the Full Year of 2022

NuVasive, Inc. to Report Q1, 2022 Results on May 04, 2022

NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet

NuVasive, Inc., Annual General Meeting, May 11, 2022

At US$56.32, Is NuVasive, Inc. (NASDAQ:NUVA) Worth Looking At Closely?

NuVasive's Turnaround Story Needs A Boost From Better Results

Full year 2021 earnings: EPS exceeds analyst expectations

NuVasive, Inc. Provides Earnings Guidance for the Full Year 2022

NuVasive, Inc. to Report Q4, 2021 Results on Feb 23, 2022

NuVasive, Inc. Appoints Andrew C. Morton as Senior Vice President and Chief Human Resources Officer, Effective February 7, 2022

Nuvasive Receives FDA Clearance for Expanded Indications of Use for Attrax Putty with Thoracolumbar Interbody Portfolio

Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

Price target decreased to US$66.19

Should You Think About Buying NuVasive, Inc. (NASDAQ:NUVA) Now?